AEON Biopharma, Inc. (AEON)

Price Chart

AEON Biopharma, Inc. (AEON) stock price: $1.09 (+0.01, +0.46%)

Why Bull

• •Recent insider buying suggests confidence in AEON's future, indicating that executives believe the company is undervalued.
• •Community sentiment has shifted positively, with many discussions highlighting AEON's innovative product pipeline and growth potential.
• •Analysts have noted strong demand in AEON's target markets, which could lead to increased revenue streams in the coming quarters.
• •Positive media coverage has emphasized AEON's sustainability efforts, resonating well with socially-conscious investors.

Why Bear

• •Concerns over supply chain disruptions have surfaced, raising questions about AEON's ability to meet demand efficiently.
• •Some community members express skepticism about AEON's market position relative to competitors, fearing potential loss of market share.
• •Recent earnings reports have shown volatility, leading to uncertainty about AEON's short-term financial health.
• •Market sentiment has been tempered by broader economic concerns, which could impact AEON's growth trajectory in the near term.

• 12 Health Care Stocks Moving In Thursday's Intraday Session
  benzinga · Jan 22, 2026
• 12 Health Care Stocks Moving In Thursday's Pre-Market Session
  benzinga · Dec 18, 2025
• 12 Health Care Stocks Moving In Thursday's Intraday Session
  benzinga · Nov 13, 2025
• Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
  benzinga · Jul 15, 2024

Rationale

AI-generated technical analysis for AEON including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Set your price target for AEON Biopharma, Inc. (AEON), choose a timeframe, and track your prediction accuracy.

Current price: $1.09

Score Factors

• Revenue Growth 5/100

  Revenue growth data is currently unavailable for this company.

• Gross Margin 5/100

  Gross margin data is currently unavailable for this company.

• Operating Leverage 4/100

  Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

• Cash Runway 5/100

  Cash position data is currently unavailable for this company.

• R&D Intensity 5/100

  R&D spending data is currently unavailable for this company.

• Insider Activity 6/100

  No significant insider buying or selling recently, which is neutral for the stock outlook.

• Short Interest 5/100

  Float and volume data unavailable for liquidity analysis.

• Price Momentum 0/100

  No bullish technical signals detected. The stock lacks upward price momentum currently.

• News Sentiment 5/100

  No sentiment data available

What does this score mean?

The MoonshotScore rates AEON's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Is AEON a good stock to buy?

Whether AEON is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the AEON MoonshotScore?

The MoonshotScore for AEON is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is AEON data updated?

AEON stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to AEON is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for AEON?

Growth catalysts for AEON Biopharma, Inc. (AEON) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes AEON Biopharma, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are AEON's main competitors?

AEON Biopharma, Inc. (AEON) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether AEON has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about AEON?

Wall Street analyst coverage for AEON includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is AEON's market cap?

Market capitalization (market cap) for AEON is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows AEON's current market cap alongside enterprise value and other valuation metrics.

How has AEON stock performed recently?

AEON's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing AEON's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in AEON?

Key risk categories for AEON include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures AEON's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling AEON?

Insider trading activity for AEON tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is AEON a good stock for beginners?

AEON Biopharma, Inc. (AEON) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is AEON for first-time investors?

Every stock carries risk, including AEON Biopharma, Inc. (AEON). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like AEON.

AEON vs S&P 500: which is better for new investors?

The S&P 500 (SPY) offers broad diversification across 500 large U.S. companies, making it a lower-risk starting point for new investors. AEON Biopharma, Inc. (AEON) is a single stock with higher potential upside but also more concentrated risk. Most financial advisors suggest new investors start with index funds like the S&P 500 and gradually add individual stocks like AEON as they gain experience. Compare AEON's MoonshotScore and volatility to the broad market before deciding.

What should beginners know before buying AEON?

Before buying AEON Biopharma, Inc. (AEON), beginners should understand: (1) the company's business model and how it makes money (see the Company Overview on this page), (2) its financial health through revenue growth and gross margins (see MoonshotScore Breakdown), (3) what analysts are saying (check the Analyst Consensus tab), and (4) the key risks (see Risk Factors). Start with a small position you are comfortable losing entirely, and consider dollar-cost averaging instead of investing a lump sum.

How much money do I need to start investing in AEON?

You can start investing in AEON Biopharma, Inc. (AEON) with as little as $1 through fractional shares, which most modern brokers offer. There is no minimum investment required. However, financial experts typically recommend only investing money you will not need for at least 3-5 years. Before buying AEON, make sure you have an emergency fund covering 3-6 months of expenses and no high-interest debt. Check the current AEON share price at the top of this page.